Mallick Parag
Known title: Chief ScientistCIK: 0001857948
Mallick Parag's purchase track record
Mallick Parag has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/8/2025 | NAUT | $10K | +4.2% | +111.2% | +18.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NAUT | ▲ Buy | Open Market | 1,500 | $1K | 5/12/2025 | View on chart |
| NAUT | ▲ Buy | Open Market | 12,000 | $9K | 5/8/2025 | View on chart |
| NAUT | ▼ Sell | Gift | 210,000 | $0 | 12/21/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Roth Capital initiates coverage on NAUT with $3.50 target
Roth Capital began tracking Nautilus Biotechnology with a Buy rating and a price target of $3.50. This new analyst note adds to the current consensus, where the average target from two analysts is $4.00. The stock is currently trading within its 52-week range of $0.72 to $4.31.
Roth Capital initiates coverage on NAUT with $3.50 target. Roth Capital began tracking Nautilus Biotechnology with a Buy rating and a price target of $3.50. This new analyst note adds to the current consensus, where the average target from two analysts is $4.00. The stock is currently trading within its 52-week range of $0.72 to $4.31.